Skip to main content

Table 4 Comparison of molecular profile of each intrinsic subtype

From: The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients

  ER/PR + HER2- ER/PR + HER2+ HER2 type Basal-like Unclassified
n OR n OR n OR n OR n OR
EGFR
Positive 16 1.0 (Ref) 5 2.77 (0.69, 9.44) 19 9.64 (3.76, 20.53) 34 104.55 (41.51, 856.77) 0 0.00 (0.00, 2.75)
Negative 283   35   39   3   28  
PTEN
Reduced 156 1.0 (Ref) 18 0.75 (0.35, 1.55) 16 0.31(0.16, 0.63) 28 2.57 (1.11, 6.37) 16 1.31 (0.55, 3.15)
Normal 140   23   42   9   12  
Bcl- 2
Positive 249 1.0 (Ref) 27 0.41 (0.19, 0.99) 7 0.02 (0.01, 0.07) 6 0.04 (0.01, 0.12) 14 0.20 (0.08, 0.49)
Negative 51   13   51   31   14  
c -Kit
Positive 15 1.0 (Ref) 0 0.00 (0.00, 2.16) 7 2.70 (0.84, 7.48) 10 7.50 (2.60, 20.96) 1 0.73 (0.02, 5.29)
Negative 287   41   51   27   27  
c- Met
Positive 203 1.0 (Ref) 34 1.98 (0.79, 5.54) 47 2.63 (1.14, 6.70) 28 1.43 (0.61, 3.60) 16 0.58 (0.23, 1.44)
Negative 89   7   8   9   11  
Survivin
Positive 240 1.0 (Ref) 34 1.32 (0.50, 4.20) 56 7.54 (1.74, 61.08) 30 1.25 (0.05, 3.52) 23 1.41 (0.46, 4.91)
Negative 62   6   2   7   5  
  1. Results are odds ratio (OR) adjusted by age and 95% confidence interval.
  2. EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor.